Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 237,809
  • Shares Outstanding, K 21,026
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,080 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.0700 +9.14%
on 03/04/25
14.2300 -22.77%
on 02/18/25
-2.5500 (-18.83%)
since 02/14/25
3-Month
10.0700 +9.14%
on 03/04/25
15.5500 -29.32%
on 01/07/25
-2.9500 (-21.16%)
since 12/13/24
52-Week
9.2500 +18.81%
on 09/19/24
24.3200 -54.81%
on 04/03/24
-11.0500 (-50.14%)
since 03/14/24

Most Recent Stories

More News
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update...

CYBN : 7.57 (+3.70%)
CYBN.NE : 10.9900 (+4.17%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 10.9900 (+4.17%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 7.57 (+3.70%)
ATAI : 1.4800 (+6.47%)
MNMD : 6.35 (+0.63%)
SEEL : 0.3900 (-27.79%)
CMPS : 3.48 (-0.29%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 7.57 (+3.70%)
CYBN.NE : 10.9900 (+4.17%)
Cybin to Acquire Small Pharma Inc.

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders...

DMTTF : 0.1117 (-9.70%)
DMT.VN : 0.150 (-6.25%)
CYBN.NE : 10.9900 (+4.17%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 10.9900 (+4.17%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 7.57 (+3.70%)
CMPS : 3.48 (-0.29%)
SEEL : 0.3900 (-27.79%)
MNMD : 6.35 (+0.63%)
NUMIF : 0.0190 (-6.40%)
NUMI.TO : 0.0500 (+42.86%)
Cybin to Participate at the 26th Annual Milken Institute Global Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 10.9900 (+4.17%)
CYBN : 7.57 (+3.70%)
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative...

CYBN.NE : 10.9900 (+4.17%)
CYBN : 7.57 (+3.70%)
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug...

CYBN.NE : 10.9900 (+4.17%)
CYBN : 7.57 (+3.70%)
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder in Psychedelics Discussions

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference;...

CYBN.NE : 10.9900 (+4.17%)
CYBN : 7.57 (+3.70%)
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® and The Chopra Foundation, a not-for-profit...

CYBN.NE : 10.9900 (+4.17%)
CYBN : 7.57 (+3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various...

See More

Key Turning Points

3rd Resistance Point 11.7533
2nd Resistance Point 11.3767
1st Resistance Point 11.1833
Last Price 10.9900
1st Support Level 10.6133
2nd Support Level 10.2367
3rd Support Level 10.0433

See More

52-Week High 24.3200
Fibonacci 61.8% 18.5633
Fibonacci 50% 16.7850
Fibonacci 38.2% 15.0067
Last Price 10.9900
52-Week Low 9.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar